Tradestie Institutional Equity Comparison Engine

ABCL vs ZBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABCL Overall Edge

ABCL Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Growth & Margin, Momentum & Technical while ZBIO counters with relative strength in Options & Structure. Fundamentally, ABCL trades at 27.6x Forward P/E with -1550.0% operating margin (-76.3% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, ABCL sits in CONSOLIDATION (29th %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ABCL
ABCL 27.6x vs ZBIO N/M Fwd P/E
Growth & Margin Winner ABCL
Op Margin -1550.0% vs -2747.5% ยท YoY -76.3% vs -100.0%
Momentum & Technical Winner ABCL
1Y +207.2% vs -21.7% ยท 52W Pos 68% vs 46%
Options & Structure Winner ZBIO
CONSOLIDATION (29th %ile IV) vs CONSOLIDATION (13th %ile IV)
ABCL NASDAQ
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.12
-3.22% 1D
Market Cap $3.8B
1M Return -5.76%
1Y Return +207.18%
Forward P/E 27.6x
Unified AI Score
63.3 / 100 BUY
Tech 57.0 Fund 58.0 Flow 67.0 Mom 54.0
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABCL +207.18% ZBIO -21.68% Spread: +228.86 pp (ABCL Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ABCL Revenue ZBIO Revenue ABCL Op. Margin ZBIO Op. Margin Margin Edge
FY2019 $10M N/A -35.5% N/A ABCL
FY2020 $230M N/A 66.9% N/A ABCL
FY2021 $380M N/A 54.5% N/A ABCL
FY2022 $490M N/A 44.6% N/A ABCL
FY2023 $40M $50M -623.8% -74.3% ZBIO
FY2024 $30M $10M -1091.7% -3277.8% ABCL
FY2025 $80M $10M -289.0% -3830.6% ABCL

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABCL (8) vs ZBIO (2)
Institutional Metric ABCL ZBIO Criterion Row Winner
Market Capitalization Scale $3.8B $1.9B Larger Scale ABCL
Trailing P/E Ratio Valuation 27.6x N/M Lower Multiple ABCL
Forward P/E Ratio Valuation 27.6x N/M Lower Multiple ABCL
Revenue Growth (YoY) Growth -76.3% -100.0% Higher Growth ABCL
Operating Margin (TTM) Profitability -1550.0% -2747.5% Higher Margin ABCL
Net Profit Margin Profitability -248.8% 0.0% Higher Margin ZBIO
Return on Equity (ROE) Capital Efficiency -17.3% -265.1% Higher ROE ABCL
52-Week Range Position Momentum 68% ($3โ€“$15) 46% ($14โ€“$45) Stronger Trend ABCL
Beta / 30D Volatility Risk Regime 2.30ฮฒ ยท 87% Vol 1.16ฮฒ ยท 59% Vol Lower Realized Risk ZBIO
Unified Institutional Score Composite Signal 63.3 / 100 (BUY) 49.4 / 100 (HOLD) Higher Composite ABCL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABCL vs ZBIO Buy Guide
ABCL CONSOLIDATION
34d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 29th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ABCL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABCL nor ZBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.